Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells

References

• Liu Q, Wang HG. Anti-cancer drug discovery and development: Bcl-2 family small molecule inhibitors. Commun Integr Biol 2012; 5:557-65; PMID:23336025; http://dx.doi.org/10.4161/cib.21554
   PubMedGoogle Scholar
• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: Cancer J Clin 2014; 64:9-29; PMID:24399786
   PubMed Web of Science ®Google Scholar
• Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 1984; 226:1097-9; PMID:6093263; http://dx.doi.org/10.1126/science.6093263
   PubMed Web of Science ®Google Scholar
• Schena M, Larsson LG, Gottardi D, Gaidano G, Carlsson M, Nilsson K, Caligaris-Cappio F. Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells. Blood 1992; 79:2981-9; PMID:1375120
   PubMed Web of Science ®Google Scholar
• Harada N, Hata H, Yoshida M, Soniki T, Nagasaki A, Kuribayashi N, Kimura T, Matsuzaki H, Mitsuya H. Expression of Bcl-2 family of proteins in fresh myeloma cells. Leukemia: Off J Leukemia Soc Am, Leukemia Res Fund, UK 1998; 12:1817-20; PMID:9823959; http://dx.doi.org/10.1038/sj.leu.2401168
   PubMed Web of Science ®Google Scholar
• Tu Y, Xu FH, Liu J, Vescio R, Berenson J, Fady C, Lichtenstein A. Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide. Blood 1996; 88:1805-12; PMID:8781438
   PubMed Web of Science ®Google Scholar
• Campos L, Rouault JP, Sabido O, Oriol P, Roubi N, Vasselon C, Archimbaud E, Magaud JP, Guyotat D. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993; 81:3091-6; PMID:7684624
   PubMed Web of Science ®Google Scholar
• Iqbal J, Neppalli VT, Wright G, Dave BJ, Horsman DE, Rosenwald A, Lynch J, Hans CP, Weisenburger DD, Greiner TC, et al. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol: Off J Am Soc Clin Oncol 2006; 24:961-8; PMID:16418494; http://dx.doi.org/10.1200/JCO.2005.03.4264
   PubMed Web of Science ®Google Scholar
• Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, Deng X, Zhai D, Shi YX, Sneed T, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006; 10:375-88; PMID:17097560; http://dx.doi.org/10.1016/j.ccr.2006.10.006
   PubMed Web of Science ®Google Scholar
• Bodet L, Gomez-Bougie P, Touzeau C, Dousset C, Descamps G, Maiga S, Avet-Loiseau H, Bataille R, Moreau P, Le Gouill S, et al. ABT-737 is highly effective against molecular subgroups of multiple myeloma. Blood 2011; 118:3901-10; PMID:21835956; http://dx.doi.org/10.1182/blood-2010-11-317438
   PubMed Web of Science ®Google Scholar
• Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013; 19:202-8; PMID:23291630; http://dx.doi.org/10.1038/nm.3048
   PubMed Web of Science ®Google Scholar
• Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, Cortes J, DeAngelo DJ, Debose L, Mu H, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov 2014; 4:362-75; PMID:24346116; http://dx.doi.org/10.1158/2159-8290.CD-13-0609
   PubMed Web of Science ®Google Scholar
• Wuilleme-Toumi S, Robillard N, Gomez P, Moreau P, Le Gouill S, Avet-Loiseau H, Harousseau JL, Amiot M, Bataille R. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia: Off J Leukemia Soc Am, Leukemia Res Fund, UK 2005; 19:1248-52; PMID:15902294; http://dx.doi.org/10.1038/sj.leu.2403784
   PubMed Web of Science ®Google Scholar
• Derenne S, Monia B, Dean NM, Taylor JK, Rapp MJ, Harousseau JL, Bataille R, Amiot M. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood 2002; 100:194-9; PMID:12070027; http://dx.doi.org/10.1182/blood.V100.1.194
   PubMed Web of Science ®Google Scholar
• Glaser SP, Lee EF, Trounson E, Bouillet P, Wei A, Fairlie WD, Izon DJ, Zuber J, Rappaport AR, Herold MJ, et al. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev 2012; 26:120-5; PMID:22279045; http://dx.doi.org/10.1101/gad.182980.111
   PubMed Web of Science ®Google Scholar
• Doi K, Li R, Sung SS, Wu H, Liu Y, Manieri W, Krishnegowda G, Awwad A, Dewey A, Liu X, et al. Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation. J Biol Chem 2012; 287:10224-35; PMID:22311987; http://dx.doi.org/10.1074/jbc.M111.334532
   PubMed Web of Science ®Google Scholar
• Czabotar PE, Lee EF, van Delft MF, Day CL, Smith BJ, Huang DC, Fairlie WD, Hinds MG, Colman PM. Structural insights into the degradation of Mcl-1 induced by BH3 domains. Proc Nat Acad Sci U S A 2007; 104:6217-22; PMID:17389404; http://dx.doi.org/10.1073/pnas.0701297104
   PubMed Web of Science ®Google Scholar
• Pandey MK, Gowda K, Doi K, Sharma AK, Wang HG, Amin S. Proteasomal degradation of Mcl-1 by maritoclax induces apoptosis and enhances the efficacy of ABT-737 in melanoma cells. PloS One 2013; 8:e78570; PMID:24223823; http://dx.doi.org/10.1371/journal.pone.0078570
   PubMed Web of Science ®Google Scholar
• Doi K, Liu Q, Gowda K, Barth BM, Claxton D, Amin S, Loughran TP Jr, Wang HG. Maritoclax induces apoptosis in acute myeloid leukemia cells with elevated Mcl-1 expression. Cancer Biol Ther 2014; 15:1077-86; PMID:24842334; http://dx.doi.org/10.4161/cbt.29186
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang W, Lu X, Xu Y, Zhang X. The stability and degradation of a new biological pesticide, pyoluteorin. Pest Manage Sci 2010; 66:248-52; PMID:19834883; http://dx.doi.org/10.1002/ps.1856
   PubMed Web of Science ®Google Scholar
• Day CL, Smits C, Fan FC, Lee EF, Fairlie WD, Hinds MG. Structure of the BH3 domains from the p53-inducible BH3-only proteins Noxa and Puma in complex with Mcl-1. J Mol Biol 2008; 380:958-71; PMID:18589438; http://dx.doi.org/10.1016/j.jmb.2008.05.071
   PubMed Web of Science ®Google Scholar
• Wang GQ, Gastman BR, Wieckowski E, Goldstein LA, Gambotto A, Kim TH, Fang B, Rabinovitz A, Yin XM, Rabinowich H. A role for mitochondrial Bak in apoptotic response to anticancer drugs. J Biol Chem 2001; 276:34307-17; PMID:11447222; http://dx.doi.org/10.1074/jbc.M103526200
   PubMed Web of Science ®Google Scholar
• Garrido SM, Appelbaum FR, Willman CL, Banker DE. Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). Exp Hematol 2001; 29:448-57; PMID:11301185; http://dx.doi.org/10.1016/S0301-472X(01)00612-9
   PubMed Web of Science ®Google Scholar
• Yamamoto-Sugitani M, Kuroda J, Ashihara E, Nagoshi H, Kobayashi T, Matsumoto Y, Sasaki N, Shimura Y, Kiyota M, Nakayama R, et al. Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia. Proc Nat Acad Sci U S A 2011; 108:17468-73; PMID:21987825; http://dx.doi.org/10.1073/pnas.1111138108
   PubMed Web of Science ®Google Scholar
• Cheung WC, Van Ness B. The bone marrow stromal microenvironment influences myeloma therapeutic response in vitro. Leukemia: Off J Leukemia Soc Am, Leukemia Res Fund, UK 2001; 15:264-71; PMID:11236942; http://dx.doi.org/10.1038/sj.leu.2402022
   PubMed Web of Science ®Google Scholar
• Balakrishnan K, Burger JA, Wierda WG, Gandhi V. AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood 2009; 113:149-53; PMID:18836097; http://dx.doi.org/10.1182/blood-2008-02-138560
   PubMed Web of Science ®Google Scholar
• Opferman JT, Iwasaki H, Ong CC, Suh H, Mizuno S, Akashi K, Korsmeyer SJ. Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science 2005; 307:1101-4; PMID:15718471; http://dx.doi.org/10.1126/science.1106114
   PubMed Web of Science ®Google Scholar
• Chen S, Dai Y, Harada H, Dent P, Grant S. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 2007; 67:782-91; PMID:17234790; http://dx.doi.org/10.1158/0008-5472.CAN-06-3964
   PubMed Web of Science ®Google Scholar
• Touzeau C, Dousset C, Le Gouill S, Sampath D, Leverson JD, Souers AJ, Maiga S, Bene MC, Moreau P, Pellat-Deceunynck C, et al. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia: Off J Leukemia Soc Am, Leukemia Res Fund, UK 2014; 28:210-2; PMID:23860449; http://dx.doi.org/10.1038/leu.2013.216
   PubMed Web of Science ®Google Scholar
• Day CL, Chen L, Richardson SJ, Harrison PJ, Huang DC, Hinds MG. Solution structure of prosurvival Mcl-1 and characterization of its binding by proapoptotic BH3-only ligands. J Biol Chem 2005; 280:4738-44; PMID:15550399; http://dx.doi.org/10.1074/jbc.M411434200
   PubMed Web of Science ®Google Scholar
• Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004; 47:1739-49; PMID:15027865; http://dx.doi.org/10.1021/jm0306430
   PubMed Web of Science ®Google Scholar
• Jorgensen WL, Maxwell DS, Tirado-Rives J. Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J Am Chem Soc 1996; 118:11225-36; http://dx.doi.org/10.1021/ja9621760
   Web of Science ®Google Scholar
• Eldridge MD, Murray CW, Auton TR, Paolini GV, Mee RP. Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J Comput-Aided Mol Des 1997; 11:425-45; PMID:9385547; http://dx.doi.org/10.1023/A:1007996124545
   PubMed Web of Science ®Google Scholar
• Krajewski S, Bodrug S, Gascoyne R, Berean K, Krajewska M, Reed JC. Immunohistochemical analysis of Mcl-1 and Bcl-2 proteins in normal and neoplastic lymph nodes. Am J Pathol 1994; 145:515-25; PMID:8080035
   PubMed Web of Science ®Google Scholar
• Cheng C, Pan L, Chen Y, Song H, Qin Y, Li R. Total synthesis of (+−)-marinopyrrole A and its library as potential antibiotic and anticancer agents. J Comb Chem 2010; 12:541-7; PMID:20429575; http://dx.doi.org/10.1021/cc100052j
   PubMed Web of Science ®Google Scholar
• Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435:677-81; PMID:15902208; http://dx.doi.org/10.1038/nature03579
   PubMed Web of Science ®Google Scholar